All Posts
How to Transition an AAV Gene Therapy Program from Adherent to Suspension Culture Safely
Transitioning an AAV gene therapy program from adherent cell culture to a suspension platform is
May 28, 2026
Transitioning an AAV gene therapy program from adherent cell culture to a suspension platform is
In the high-stakes ecosystem of the life sciences industry, ensuring product safety, efficacy, and consistency
Grant Writing · Pharma & Drug Development · Complete Guide The Complete Guide
When a pharmaceutical or life sciences company receives a Form 483, Warning Letter, or Consent
Pharmacovigilance consulting has become a cornerstone of modern drug development and post-market surveillance. As regulatory
BOSTON, MA — May 6, 2026 — DES Pharma, a premier provider of strategic advisory
The countdown has officially begun. From May 11–14, 2026, the global biopharmaceutical community will descend
Biotech is the rare industry where a single decision — a missed FDA meeting, a
The pharmaceutical landscape is evolving rapidly, and staying ahead of the curve means keeping a
The Critical Bridge in Drug Development Technology transfer stands as one of the most pivotal—yet
Start building reliable, high-quality drug development programs today.